A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

To assess the safety and tolerability of Dimebon, 20 mg three times a day (TID), during 90 days of treatment in subjects with Huntington’s disease (HD).

Critère d'inclusion

Huntington's disease

Liens

ictrp
euctr